Ruti Aga and the Full Arithmetic of Six Years: Two for the Drug, Four for a Forged Prescription

A half marathon was won in China in March. The winner was Ruti Aga, an Ethiopian marathoner, 32. The time is not in any official statement — no splits, no field depth, no temperature, no timing method. What is recorded is this: the in-competition sample from that race returned methylprednisolone, and on Thursday the Athletics Integrity Unit (AIU) announced a six-year ban.

When a sanction release names the punishment but not the result, my first job is to add up the punishment and my second is to identify which number is missing. Six years is the headline number. The real number is not 6; it is 2+4. And the larger point sits behind that arithmetic: in this case the career was not ended by a drug, but by a document.

The first pass looked ordinary; the second pass found the pattern. I do not write the number until I can rebuild the number.

Context: the agency, the code, and one mislabelled word

The ban was imposed under the World Athletics Anti-Doping Rules, enforced by the AIU, applying the WADA Code and the WADA Prohibited List. That background matters because the biggest technical fact in this case is the one the early reporting got wrong.

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid — class S9 on the WADA Prohibited List. And S9 substances are prohibited by injection, oral or rectal route in competition only. The same injection given out of competition is entirely lawful. That is not a footnote about vocabulary; it is the hinge of the whole case. A text that calls it a steroid files this matter into the anabolic category, where the reasoning around sanction length runs on completely different tracks.

The stated explanation was a knee injury. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners, so the explanation was mechanistically credible. The moment a prescription was fabricated to support it, credibility became the lethal fact — a genuine treatment produces genuine records, and genuine records do not need to be invented.

The evidence chain: two years, four years, and three failures of verification

The sanction architecture is standard, not exceptional. Two years for the presence violation — consistent with a Specified Substance finding where intent was not proven. Four years for tampering — the Code's standard penalty. The sum is clean. But the sum carries a second meaning: the panel declined the reduction that a no-significant-fault argument could have produced. A forged document is itself circumstantial evidence of concealment, and the panel treated it as fully culpable.

Now the part that gets skipped when the story is told as a prescription anecdote — the verification chain. The prescription carried the name of a clinic that did not exist. The person who wrote it was a family member with no medical registration. When questioned, that person claimed to have used an old prescription pad from a former workplace, and the clinic explicitly disowned the claim. Three independent points of verification failed, and all three point the same way: the athlete was operating without a credentialed team physician. This is not a filing error; it is the signature of a medical-governance vacuum.

This is where the substance classification becomes decisive. Because S9 glucocorticoids are prohibited in competition only, a legitimate defence existed: documented route, documented timing, documented medical necessity, or a Therapeutic Use Exemption. In a road race the in-competition window opens at 23:59 the day before the race, so an injection given days earlier can still be caught — a manageable interval, provided someone is managing it. Nobody was.

What survives and what does not

The loudest absence in the statement is the scope of disqualification. Standard practice voids the result and prize money from the competition at which the sample was collected, plus ranking points accrued afterwards. Earlier results do not fall automatically. The 2026 Tokyo Marathon title and three World Marathon Majors runner-up finishes remain on the record, because the violation is anchored to a later race and not to a finding of earlier use. (A second place at Berlin 2026 in roughly 2:18:34, and 2:20:40 at Tokyo 2026, sit in my external notes pending verification — I keep those in brackets rather than in the sentence, because this article rests on the statement, not on my memory.)

The age line is unforgiving. Thirty-two now, six years out, a return at roughly 38. Ethiopian women's marathon depth is such that a 2:18-class runner is not automatically selectable; after a ban, the question is not even practical. The sanction cuts through the entire 2028 Olympic cycle.

Then there is the economic layer I always look for on this beat — the payroll beneath the podium. Aga's post-2026 pattern was selective Major racing plus Asian label-race appearances: low race count, high appearance fee. China's label-race circuit is the income tier between Majors for East African marathoners. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and in this case the collision produced a forged prescription.

The contrarian angle: the length did not come from the drug

Six years for a substance with no proven endurance benefit looks disproportionate at first glance. Care is required here. Framing this as the AIU being harsh on African road runners is easy, but the claim only holds if someone shows the arithmetic. The length came from the document, not the drug. What cost six years was not methylprednisolone; it was the prescription.

On the other side, the sentence 'the federation left her alone' is empty unless a mechanism is named. Here the mechanism is visible: no credentialed team physician, no TUE infrastructure, no formal medical referral chain. This is not a comparison with UK Athletics structures; it is a description of the informal medical network that serves several training clusters at once. That is also why I read this as a member of a recognisable case family rather than an isolated event — an initial substance violation compounded by a fabricated explanation. But caution: case clustering is a hypothesis, not a finding. Correlation does not become causation, and I am keeping this in the hypothesis drawer.

One thing cost me in 2026: I killed a colleague's injury report because it had no numbers, and it turned out to be the most important story of the lockdown. Since then I hold one slot a month for a story I cannot quantify. This case belongs in that category. The knee injury is probably real and chronic, and it is the actual root cause: the pressure to mask a painful race, the cheapest available tool, and an informal support network. All three delivered this ending.

What to watch next

An appeal window exists — roughly 21 days from the reasoned decision to the Court of Arbitration for Sport — but a document-based finding is hard to overturn, so the appeal has low value. What I will track: whether the AIU publishes the disqualification scope separately; whether any investigation of the agent or management is mentioned; whether the Ethiopian federation says a single sentence. And one trend: the enforcement frontier is shifting from detection to document verification. The race that gets audited next will be run on paper.

What would change my mind: if the full reasoned decision shows the panel treated the prescription as an identity error, or if a valid TUE predating the race turns out to have existed, the whole reading gets rewritten. Until then, the raw file stays open.

One question is still waiting for an answer: if filing genuine medical paperwork might have cost two years, who convinced her that fake paperwork would save her?